Key features and details
- Potent A1 antagonist
- CAS Number: 102146-07-6
- Purity: > 99%
- Soluble in ethanol to 10 mM and in DMSO to 5 mM
- Form / State: Solid
- Source: Synthetic
Product nameDPCPX, A1 antagonist
DescriptionPotent A1 antagonist
Potent A1antagonist (Ki = 0.45 nM). Also exhibits antagonism at A2B receptors (pA2 = 7.16, for human A2B expressed in CHO cells).
Storage instructionsStore at Room Temperature. The product can be stored for up to 12 months.
Solubility overviewSoluble in ethanol to 10 mM and in DMSO to 5 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab120396 has been referenced in 13 publications.
- Wang W et al. Inhibition of adenosine kinase attenuates myocardial ischaemia/reperfusion injury. J Cell Mol Med 25:2931-2943 (2021). PubMed: 33523568
- Lv YC et al. Long-term adenosine A1 receptor activation-induced sortilin expression promotes a-synuclein upregulation in dopaminergic neurons. Neural Regen Res 15:712-723 (2020). PubMed: 31638096
- Yi X et al. Adenosine receptors enhance the ATP-induced odontoblastic differentiation of human dental pulp cells. Biochem Biophys Res Commun 497:850-856 (2018). PubMed: 29454963
- Kashfi S et al. Purinergic Receptor Expression and Potential Association with Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cell Development. Cell J 19:386-402 (2017). PubMed: 28836401
- Zhou Y et al. The Adenosine A1 Receptor Antagonist DPCPX Inhibits Tumor Progression via the ERK/JNK Pathway in Renal Cell Carcinoma. Cell Physiol Biochem 43:733-742 (2017). PubMed: 28950257